Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.42 |
| ▸ | HTR2A | P28223 | 1/20 | 0.42 |
| ▸ | HTR2C | P28335 | 1/20 | 0.42 |
| ▸ | HTR2B | P41595 | 1/20 | 0.42 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.42 |
| ▸ | KDM1A | O60341 | 2/20 | 0.34 |
| ▸ | MAOB | P27338 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3169552 | 0.72 | SIGMAR1 (0.44) | SIGMAR1HTR2AHTR2CHTR2BTMEM97 | |
| Hydrochloric Acid SCHEMBL27492472 | 0.71 | SIGMAR1 (0.43) | SIGMAR1HTR2AHTR2CHTR2BTMEM97 | |
| SCHEMBL14182622 | 0.67 | SIGMAR1 (0.43) | SIGMAR1HTR2AHTR2CHTR2BTMEM97 | |
| SCHEMBL11395065 | 0.67 | SIGMAR1 (0.47) | SIGMAR1HTR2AHTR2CHTR2BTMEM97 | |
| SCHEMBL30664080 | 0.65 | KDM1A (0.50) | HTR2AKDM1AMAOBTSHR | |
| SCHEMBL30316454 | 0.65 | KDM1A (0.50) | HTR2AKDM1AMAOBTSHR | |
| SCHEMBL29529186 | 0.65 | KDM1A (0.50) | HTR2AKDM1AMAOBTSHR | |
| SCHEMBL2147836 | 0.65 | KDM1A (0.50) | HTR2AKDM1AMAOBTSHR | |
| SCHEMBL788818 | 0.65 | KDM1A (0.50) | HTR2AKDM1AMAOBTSHR | |
| SCHEMBL594461 | 0.65 | KDM1A (0.50) | HTR2AKDM1AMAOBTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6384244-B2 | HYDROGENATING OXIME IN PRESENCE OF A CATALYST AND AN ACID; USEFUL AS CHEMICAL INTERMEDIATES IN PRODUCTION OF HIV PROTEASE INHIBITORS | MERCK & CO., INC. | 2002-05-07 | — | — | US | disclosed |
| US-20010056193-A1 | Process for preparing cis- aminochromanols | MERCK & CO., INC. | 2001-12-27 | — | — | US | disclosed |
| WO-2001087873-A1 | PROCESS FOR PREPARING CIS-AMINOCHROMANOLS | MERCK & CO., INC. (US) | 2001-11-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010056193-A1 | Process for preparing cis- aminochromanols | SRR, GRHPR, SPR | SIGMAR1 1261/4885HTR2A 3711/4885HTR2C 3359/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.